Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
The US military wants to grow its own supplies using microbes instead of supply chains. Biosphere portable bioreactor contract shows how.
Profluent, Cradle, and Latent Labs have raised $347M combined to build frontier AI models that design proteins from scratch. The thesis: protein engineering is becoming a platform industry, and software-infrastructure investors are betting it follows the same playbook as cloud computing.
$1.1 billion. That is what 23 startups have raised to automate cell therapy manufacturing. Now DARPA is pushing autonomous biomanufacturing for defence, and the two trends are converging. Cellares, Ori Biotech, Multiply Labs, and Streamline Bio are racing to build the factory of the future.
AI-designed base editors enter clinical validation. Beam Phase 1/2 BEAM-302 data restores AAT above protective thresholds. Profluent secured $150M plus $2.25B Lilly deal. ARPA-H committed $160M through THRIVE. Compact editors like SsdAtox fit AAV vectors, measured by the BEPI index.
Caplight $16M Series A led by BlackRock and Fin Capital signals institutional-grade infrastructure for a $12T private market asset class.
Dyno Therapeutics has become the first company to license AI-designed AAV capsids for both CNS and muscle gene therapies. The Astellas deal, with a $15 million upfront fee, validates that AI-designed biological sequences can pass Big Pharma's diligence process.
Dyno Therapeutics has become the first company to license AI-designed AAV capsids for both CNS and muscle gene therapies. The Astellas deal, with a $15 million upfront fee, validates that AI-designed biological sequences can pass Big Pharma's diligence process.
Generative AI has discovered nearly a million antimicrobial peptide candidates in two years. The bottleneck has shifted from discovery to delivery and MIT programmable antibacterials point to a path forward.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
